| Name | Title | Contact Details |
|---|
PanCare Health Offers Health Care Services In Multiple Locations, Including Freeport And Bonifay, FL For Urgent Care, Affordable Therapy, And More. Call Today!
Celyad is a clinical-stage biopharmaceutical company focused on the identification and development of specialized cell based therapies. With product candidates in oncology and cardiology, Celyad seeks to address diseases with high unmet medical needs such as heart failure and cancer. Founded in 2007, Celyad leverages unique know-how in taking cell based therapies from bench to Phase III, as well as the manufacturing and logistical infrastructure for such complex products. Celyad builds it business model on partnering with prominent research institutions such as the Mayo Clinic and Dartmouth College, and develops those programs from bench to commercial applications.
Psych Hub is the worlds largest online platform for mental health education. We train mental health providers, employers, organizations, and individuals on mental health.
PACT Pharma is an independent, privately funded company recently launched by Arcus and scientific founders Jim Heath (Caltech), Toni Ribas (UCLA) and David Baltimore (Caltech). PACT`s vision is to be the leader in creating, developing and commercializing cell-based therapies for the cure of cancer. Our mission is to leverage technology developed in the laboratories of Jim Heath and David Baltimore to advance the feasibility, affordability and clinical utilization of personalized neoantigen-specific adoptive cell therapy for cancer. PACT is developing personalized adoptive T cell therapies for the eradication of solid tumors. The identification of neo-epitopes that serve as private mutations for each patient`s cancer creates a unique opportunity to engineer autologous T cells that target and kill tumors expressing these neo-antigens. PACT utilizes technology to identify T cells that recognize the neo-epitope. The unique T-cell receptor (TCR) sequences obtained from these neo-epitope-reactive cells are then engineered into T cells from the patient`s own blood to produce PACT`s therapeutic product: a tsunami of fresh, active T cells that, following infusion into the patient, recognize and attack each patient`s cancer cells.